Vertex planning triple combo CF trials on heels of Phase II data

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it will begin shortly a pair of Phase III trials evaluating a fixed-dose combination of VX-445, tezacaftor (VX-661) and Kalydeco ivacaftor to treat cystic fibrosis. The trials are supported by Phase II data of

Read the full 393 word article

User Sign In